Loading
A phase 2 trial of SI-B001, Cisplatin, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. is a phase 2 interventional study registered as NCT05020457 by Sichuan Baili Pharmaceutical Co., Ltd., with 69 participants enrolled, started 2021-12-07 and due to reach its primary completion in 2025-12. Interventions recorded: SI-B001, AP or TP, Docetaxel. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares SI-B001, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares SI-B001, SystImmune / Sichuan Biokin, Non-small-cell lung cancer.
Shares SI-B001, SystImmune / Sichuan Biokin.
Shares SI-B001, SystImmune / Sichuan Biokin, Docetaxel.
Shares SystImmune / Sichuan Biokin, Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
Shares SI-B001, SystImmune / Sichuan Biokin, Docetaxel.
Shares SI-B001, SystImmune / Sichuan Biokin.
Shares SI-B001, SystImmune / Sichuan Biokin.